攝護腺癌之荷爾蒙治療可能增加失智症的風險
古筱菁1,4、詹鎮豪1,4、楊淵韓3、張郁函3、蔡嘉駿1,2,4
1高雄醫學大學 附設中和紀念醫院 泌尿科
2高雄市立大同醫院 泌尿科
3高雄市立大同醫院 神經科
4高雄醫學大學 醫學系
Hormone therapy for prostate cancer increases the risk of Alzheimer’s disease: a nationwide 4-year longitudinal cohort study
Shiao-Jin Guu 1,4、Jhen-Hao Jhan 1,4、Yuan-Han Yan 3、Yu-Han Chang 3、Chia-Chun Tsai 1,2,4
1 Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
2 Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan
3 Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan
4Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Purpose: To investigate the risk of developing Alzheimer’s disease (AD) in patients undergoing ADT for prostate cancer.
Materials and Methods: Data from 24 360 prostate cancer patients were collected from the Longitudinal Health Insurance Database of Taiwan. In total, 15 959 patients who underwent ADT were included in the study cohort, and another 8401 patients who did not receive ADT were included as a non-ADT cohort.
Results: During the average 4-year follow-up period, the incidence of AD was 2.78 per 1000 person-years in the non-ADT cohort and 5.66 per 1000 person-years in the ADT cohort. After adjusting for age and all comorbidities, the combined ADT cohort was found to be 1.84 times more likely to develop AD than the non-ADT control group (95%CI 1.33–2.55, p < 0.001).
Conclusions: The present results suggest that ADT use is associated with an increased risk of developing AD